Clinical trials: Covid19 Vaccine
Covid-19
Antibodies Response to mRNA Vaccine Against Covid-19
Vaccine rollout has started in many countries. In Italy, the Covid-19 vaccine used at the moment is the mRNA-based BNT162b2 and is given to Hospital employers.
- Trial name
- SCAREAID (NCT04733807)
- Testing
- BNT162b2 mRNA Covid-19 Vaccine
- Where
- Italy
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- University of Roma La Sapienza
Health Care Utilization, Vaccine Preventable Disease
Effect of Varied Outreach Methods on Appointment Scheduling, Appointment Completion, and Receipt of COVID-19 Vaccination
Our objective is to determine the effectiveness of varied outreach methods to children age 12-17 years old who are due for a well child check visit and don't have one scheduled in the next 45 days on the outcomes of appointment…
- Trial name
- NCT04904744
- Testing
- Low tailored message, No message, Low tailored message plus COVID-19 vaccine message
- Where
- United States
- Volunteers
- 1,235 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
COVID-19, SARS-CoV-2 Infection
A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses
The goal of this clinical trial is to test two investigational COVID-19 booster vaccines, called CoTend-s3BXBB and CoTend-BXBB, in healthy volunteers ages 40-64.
- Trial name
- CONTENDER (NCT06810934)
- Testing
- CoTend-BXBB (SARS2-30404), CoTend-s3BXBB (SARS2-17032)
- Where
- 2 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Kara Chew
Kidney Transplant Recipients
COVID-19 Protection After Transplant Pilot Study
Antibodies are an important part of the body's defense against infection. Individuals who have no antibodies or very low antibody levels are considered less well protected from Coronavirus Disease 2019 (COVID-19) than those who…
- Trial name
- CPAT (NCT04969263)
- Testing
- BNT162b2 vaccine (Pfizer/BioNTech), mRNA-1273 vaccine (Moderna)
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Covid19, Influenza
Increasing COVID-19, Influenza, and Pneumonia Vaccine Uptake
This proposed study seeks to community knowledge and understand the experience of underserved communities in the exploration of reducing health disparities and increasing vaccine uptake and acceptability COVID-19, influenza, and…
- Conditions
- Covid19, Influenza, Pneumonia, Vaccine Refusal
- Trial name
- NCT04761692
- Testing
- Full VEPMP Intervention, Partial VEPMP Intervention, Delayed VEPMP Intervention
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Charles Drew University of Medicine and Science
COVID-19
Non-specific Effects of FLU-MMR Vaccines in Adults
Various observational studies have reported an association between influenza vaccination and lower rates of infection with SARS-Cov-2 and less COVID-19 disease severity have been reported in large epidemiological studies in US…
- Trial name
- FLUMMR-BRA (NCT05401448)
- Testing
- Influenza, MMR vaccines
- Where
- Brazil
- Volunteers
- 638 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
COVID-19 Pneumonia, Coronavirus Infections
Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above
This is randomized, blinded and controlled design. Among the randomly selected subjects who have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell), based on a step-wise approach, the subjects will receive…
- Trial name
- NCT05033847
- Testing
- Recombinant COVID-19 Vaccine (CHO cell), COVID-19 vaccine (Vero cells)
- Where
- United Arab Emirates
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
COVID-19
Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines
A phase 1/2, open-label clinical trial in individuals, 18 years of age and older, who are in good health, have no known history of Coronavirus Disease 2019 (COVID-19) or Severe Acute Respiratory Syndrome Coronavirus 2…
- Trial name
- NCT04889209
- Testing
- Ad26.COV2.S, BNT162b2, mRNA-1273
- Where
- 10 sites in United States
- Volunteers
- 867 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
PROmotion of COVID-19 BOOSTer VA(X)Ccination in the Emergency Department - PROBOOSTVAXED
The goal of this cluster randomized clinical trial is to test the efficacy of messaging interventions to increase booster vaccine uptake in adults in the emergency department(ED).
- Trial name
- PROBOOSTVAXED (NCT06156215)
- Testing
- Vaccine Messaging, Vaccine Acceptance Question
- Where
- 7 sites in United States
- Volunteers
- 919 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
COVID-19, Trust
Community-Led COVID-19 Testing Intervention to Address Mistrust
The goal of this adapted intervention study is to assess how community-led group discussions about health-related topics may alter beliefs and intentions regarding healthcare recommendations, such as COVID-19 testing and…
- Trial name
- NCT07166770
- Testing
- Community-led discussion
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Old Dominion University
HIV Infections
Vaccines in a Time of Dual Pandemic: COVID-19 Vaccine in People With HIV
This is a prospective, non-randomized observational study to examine SARS-CoV-2 vaccine immunogenicity, immune activation and HIV reservoirs in people with HIV infection in comparison with HIV-negative individuals, in those aged…
- Trial name
- NCT06731127
- Where
- Canada
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- University of Toronto
COVID-19
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19 Omicron) mRNA Vaccine (Phase 1)
A Phase I clinical study to evaluate the safety, tolerability, and immunogenicity of SARS-CoV-2 variant (Omicron) mRNA vaccine which is used to prevent COVID-19 caused by severe acute respiratory syndrome coronavirus 2…
- Trial name
- NCT05433194
- Testing
- ABO1009-DP
- Where
- United Arab Emirates
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Suzhou Abogen Biosciences Co., Ltd.
Anti-SARS-CoV-2 Antibody Response
Detection and Characterization of Anti-SARS-CoV-2 Salivary Antibodies After COVID-19 Booster Vaccines
The investigators aim to evaluate the ability of a COVID-19 (Coronavirus disease) booster vaccine to induce a salivary antibody response and investigate a possible correlation with the serum antibody response and the cellular…
- Trial name
- CoVVacBoost (NCT05142540)
- Testing
- blood and saliva samples will be taken
- Where
- Austria
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
Coronavirus, Covid19
A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19
The primary objective of this study is to evaluate the humoral immune response to CVnCoV in elderly adults aged ≥65 years and younger adults aged 18-45 years, 14 days after the second dose administration.
- Conditions
- Coronavirus, Covid19, SARS-CoV-2, Severe Acute Respiratory Syndrome
- Trial name
- NCT04838847
- Testing
- CVnCoV Vaccine
- Volunteers
- healthy volunteers welcome
- Sponsor
- CureVac
Patient Engagement, COVID-19
Collaborative Open Research Initiative Study (CORIS-1)
The Collaborative Open Research Initiative Study (CORIS) is a groundbreaking international research endeavor aimed at exploring vital topics within the field of health professions education.
- Conditions
- Patient Engagement, COVID-19, Preventable Disease, Vaccine, Burnout, Professional
- Trial name
- CORIS-1 (NCT06357650)
- Testing
- No intervention. This is an observational study
- Volunteers
- 15,000 people
- Sponsor
- Chisquares Incorporated
Multiple Sclerosis
Vaccine-generated Immunity in Ocrelizumab-treated Patients: Longitudinal Assessments (VIOLA)
Severe acute respiratory coronavirus 2 (SARS-CoV-2) is a novel coronavirus and the causative agent of COVID 19 disease, whose presentation symptoms range from asymptomatic infection to mild flu-like symptoms to multi system…
- Trial name
- NCT04843774
- Testing
- SARS-COV-2 mRNA Vaccine
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- NYU Langone Health
COVID-19
Multisite Observational Maternal and Infant Study for COVID-19
This is an observational, non-interventional, prospective cohort study designed to collect clinical information and specimens to evaluate the immune responses from pregnant individuals and postpartum individuals and their infants…
- Trial name
- MOMI-Vax (NCT05031468)
- Testing
- Licensed or EUA SARS-CoV-2 vaccine
- Where
- 10 sites in United States
- Volunteers
- 562 people, healthy volunteers welcome
- Sponsor
- Emory University
COVID-19
Safety and Immunogenicity of Inactivated Heterologous Booster Vaccination
Data from some studies indicate the decline in the effectiveness of the authorized COVID-19 vaccines due to antibody waning following vaccination and the emergence of different variants.
- Trial name
- NCT05545683
- Testing
- VLA 2001
- Where
- Colombia
- Volunteers
- healthy volunteers welcome
- Sponsor
- Centro de Estudios en Infectogía Pediatrica
Systemic Allergic Reaction
The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose
Background: Some people have allergic reactions to COVID-19 mRNA vaccines. Researchers want to learn more about these reactions to provide guidance on who can safely receive the vaccines, including a second dose in people who had…
- Trial name
- NCT04977479
- Testing
- Pfizer-BioNTech COVID-19 Vaccine (Comirnaty), Pfizer-BioNTech COVID-19 Vaccine, Bivalent
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
Study on Antibody Persistence and Immune Memory of Inactivated COVID-19 Vaccine
The study describe 1 year durability of humoral and cellular immune responses in 150 individuals who received COVID-19 inactivated vaccine. all participants were recruited aged between 18 and 59 years old.
- Trial name
- NCT05072496
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention, China
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.